Vorteil für Chemo plus PD-1-Antikörper beim fortgeschrittenen SCLC

This is a preview of subscription content, access via your institution.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Christine Starostzik.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Starostzik, C. Vorteil für Chemo plus PD-1-Antikörper beim fortgeschrittenen SCLC . Im Fokus Onkologie 24, 48–49 (2021). https://doi.org/10.1007/s15015-020-3357-3

Download citation